pharmaceuticals – Market Industry Forecast News

Bipolar Disorder Market Performance: Evaluating Drug Efficacy and Safety

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient’s mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation’s Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Access the Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient’s mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights

The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.

The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.

The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.

North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.

Order your free sample copy of “Bipolar Disorder Market Report 2024 – 2030, published by Grand View Research

Key Bipolar Disorder Company Insights

Some of the major companies in the global bipolar disorder market are AstraZeneca, Eli Lilly and Company, GSK plc, Johnson & Johnson Services, Inc., Pfizer, Inc. Companies are focusing on developing medicines and therapies in order to target various type of cancers. Companies are also focusing on reducing the side effects of medicines and treatments involved in treating bipolar disorders.

Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with health care providers, governments and local communities to support and expand access to health care around the world.

AstraZeneca plc is a pharmaceutical and biotechnology company, which offers products for various major diseases such as oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.

Key Bipolar Disorder Companies:

The following are the leading companies in the bipolar disorder market. These companies collectively hold the largest market share and dictate industry trends.

AstraZeneca
Eli Lilly and Company
GSK plc
Johnson & Johnson Services, Inc
Pfizer Inc.
AbbVie Inc.
Otsuka Holdings Co., Ltd.
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries Ltd.
Sumitomo Pharma America, Inc.

Recent Developments

In December 2023, Bristol-Myers Squibb Company acquired Karuna Therapeutics, a biopharmaceutical company that develops medicines related to psychiatric and neurological conditions. This acquisition strengthened the neuroscience portfolio of Bristol-Myers Squibb Company.

About Grand View Research:

Grand View Research, Inc. is a market research and consulting company that provides off-the-shelf, customized research reports and consulting services. To help clients make informed business decisions, we offer market intelligence studies, ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials, and energy. With a deep-seated understanding of varied business environments, Grand View Research provides strategic objective insights. For more information, visit www.grandviewresearch.com

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone:-1-415-349-0058

Email: sales@grandviewresearch.com

Anterior Uveitis Treatment Market Demand Rises with New Drugs

The global anterior uveitis treatment market size is expected to reach USD 967.5 million by 2030, registering a CAGR of 12.6% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of the disease is anticipated to aid market growth. This disease is more common when compared to panuveitis, posterior, and intermediate uveitis.

According to a 2017 article by Retina Today, this condition accounted for around 30% to 90% of the cases of uveitis. It also stated around 1% to 4% of patients experience 25% loss of visual acuity. There are different effective treatments for this disease and can be easily managed; however, it tends to recur. This disease is prevalent among both young and middle-aged group. It is also common among the geriatric population. Ocular ischemia and herpetic uveitis are the two most common causes of this disease among the geriatric population. Most of the cases occur in healthy people, however, some are associated with infectious diseases, gastrointestinal disorders, rheumatologic diseases, and lung & skin diseases. This disease is less sight-threatening as compared to posterior uveitis, however, in some cases might lead to glaucoma, cataract, and cystoid macular edema.

Access the Anterior Uveitis Treatment Market Size, Share & Trends Analysis Report By Type (Infectious Uveitis), By Therapy (Biologics), By Distribution Channel (Hospital, Retail, Online Pharmacies), By Region, And Segment Forecasts, 2024 – 2030

Anterior Uveitis Treatment Market Report Highlights

Corticosteroids dominated the anterior uveitis treatment market in 2023 owing to its beneficial characteristic of minimizing inflammation in the eye. It is the primary treatment modality.

Anti-TNF agents are expected to exhibit lucrative growth rate over the forecast period due to growing opportunity in treatment methods with biologic therapy using Anti-TNF drugs.

Immunosuppressants held a significant market share in 2023 owing to their growing adoption for treatment of chronic anterior uveitis.

Hospital pharmacies dominated the market in 2023 due to the wide treatment options available there.

Online pharmacies are expected to witness significant CAGR over the forecast period due to convenience, ease, and availability of discounted products.

North America held the largest revenue share in 2023 owing to high prevalence as well as healthcare expenditure in this region.

Asia Pacific is anticipated to exhibit lucrative growth during the forecast period due to the rising number of infectious diseases in developing countries of the region and growing disposable income.

Order your free sample copy of “Anterior Uveitis Treatment Market Report 2024 – 2030, published by Grand View Research

Key Anterior Uveitis Treatment Company Insights

Some of the key companies in the Anterior Uveitis Treatment market include Novartis AG, Santen Pharmaceutical Co., Ltd., AbbVie Inc., Kiora Pharmaceuticals, Inc., Clearside Biomedical, Aldeyra Therapeutics, Inc., UCB S.A., Agilent Technologies, Inc. (Lux Biosciences, Inc)., Tarsier Pharma Ltd. Key manufacturers are increasingly adopting strategic initiatives such as new product development, mergers & acquisitions, and regional expansion. For instance, in 2024, Kiora Pharmaceuticals, Inc. announced the results from phase I clinical trial of KIO-101 and plans for phase II clinical trial of KIO-104 for intravitreal delivery into the retina for treating posterior non-infectious uveitis.

AbbVie Inc. is actively functioning in the eye care segment. It has a wide range of products to treat various ophthalmic conditions. One of the prime products of the company for treating uveitis is “Humira” which is widely accepted as an effective treatment worldwide.
Kiora Pharmaceuticals, Inc. is exclusively involved in developing therapies for inherited and inflammatory retinal diseases. There are advanced products present in their pipeline to treat anterior uveitis.

Key Anterior Uveitis Treatment Companies:

The following are the leading companies in the anterior uveitis treatment market. These companies collectively hold the largest market share and dictate industry trends.

Novartis AG
Santen Pharmaceutical Co., Ltd.
AbbVie Inc.
Kiora Pharmaceuticals, Inc.
Clearside Biomedical
Aldeyra Therapeutics, Inc.
Aciont Inc.
Sirion Therapeutics, Inc.
UCB S.A.
Lux Biosciences, Inc.
Tarsier Pharma Ltd.

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com

Osteoporosis Drugs Market: Key Players Shaping the Future Landscape

The global osteoporosis drugs market size is expected to reach USD 18.80 billion by 2030 and is projected to grow at a CAGR of 3.5% from 2024 to 2030, according to a new report by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.

In addition, growing number of patent expiries is fueling the high clinical urgency to use generic versions of the established drugs, which is presumed to fuel generic osteoporosis drugs market during the forecast period. The aforementioned factors cumulatively are slated to present the with high potential growth opportunities over the coming years.

Furthermore, rising number of initiatives to increase the awareness levels pertaining to osteoporosis care amongst the patients as well as the physicians is expected to widen the osteoporosis market growth potential during the forecast period. For instance, National Osteoporosis Foundation (NOF), a healthcare organization responsible for National Bone Health Alliance and Fracture Liaison Service (FLS) care coordination programs that focuses on elevating awareness levels as well as provides training to healthcare professionals

Access the Osteoporosis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Branded, Generics), By Type (Bisphosphates, Parathyroid Hormone Therapy), By Distribution Channel, By Region, And Segment Forecasts, 2024 – 2030

Osteoporosis Drugs Market Report Highlights

Branded drugs held the dominant share of the product segment in 2023. The dominant share can be attributed to extensive utilization of bisphosphates, rank ligand inhibitors for the treatment of osteoporosis, possessing high efficacy

Generics are expected to witness at a lucrative CAGR owing to consistent patent expiries over the coming years as well as high clinical urgency for inexpensive medication in the emerging economies

In 2023, North America accounted for the largest share in the global osteoporosis drugs market owing to the presence of established companies extensively involved in the commercialization of branded therapeutics

Asia Pacific is anticipated to grow at an exponential CAGR as a consequence of favorable government initiatives promoting information pertaining to osteoporosis care

The key participants are employing sustainability strategies promoting the adoption of osteoporosis therapeutics to gain competitive advantage. For instance, Actavis Inc. announced to acquire Warner Chilcott PLC in order to widen their product portfolio

Order your free sample copy of “Osteoporosis Drugs Market Report 2024 – 2030, published by Grand View Research

Key Osteoporosis Drugs Company Insights

Some key companies in the osteoporosis drugs market include Amgen Inc; Eli Lilly and Company; Merck & Co., Inc.; Novartis AG; GlaxoSmithKline plc; Pfizer Inc.; Radius Health Inc.; UCB S. A.; Teva Pharmaceuticals Industries Ltd. in the market are focusing on the development of osteoporosis drugs to gain a competitive edge in the industry. Therefore, key players are taking several strategic initiatives.

Amgen Inc. develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicine for treating cardiovascular conditions, oncology/hematology, inflammation, bone health, neurological disorders, and nephrology conditions.

Novartis AG manufactures pharmaceutical and consumer healthcare products. The Company uses innovative science and digital technologies to create transformative treatments in areas of great medical need. Novartis offers patent-protected prescription medicines, generic pharmaceuticals, and biosimilars.

Key Osteoporosis Drugs Companies:

The following are the leading companies in the osteoporosis drugs market. These companies collectively hold the largest market share and dictate industry trends.

Amgen Inc.
Eli Lilly and Company
Merck & Co., Inc.
Novartis International AG
Pfizer Inc.
GlaxoSmithKline plc
Radius Health, Inc.
UCB S.A.
Teva Pharmaceutical Industries Ltd.
Roche Holding AG

About Grand View Research:

Contact:

Sherry James

Corporate Sales Specialist, USA

Grand View Research, Inc.

Phone: 1-415-349-0058
Email: sales@grandviewresearch.com